surpass trial tirzepatide SURPASS-CVOT Published: Large Confirms CVD Efficacy of 💡 New insight in diabetes

1 1000 GDU ( )

But the fact is that the Cochrane Review of the use of Oral tablets to treat PA is not at all substantial

Between-drug comparisons yielded non-statistically significant results, except for tirzepatide 15mg versus semaglutide 1.0mg (39% increased vomiting risk) and 0.5mg (85% increased vomiting risk), and tirzepatide 15mg versus semaglutide 0.5mg (45% increased risk of nausea)

MiRNA-506 Inhibits Rheumatoid Arthritis Fibroblast-Like Synoviocytes Proliferation and Induces Apoptosis by Targetting TLR4

But this actually reminds me more of the current craze for steroids and TRT

Each patient in the GLP-1RA group was matched to 1 or more (at most 4) counterparts in the DPP-4i group